Comparative Effectiveness of Bariatric Surgery Versus GLP‐1 Receptor Agonists in Reducing the Risk of New‐Onset of NASH: A Retrospective Multinational Cohort Study From North America and Europe
ABSTRACT Background Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) that can progress to cirrhosis and hepatocellular carcinoma (HCC). Obesity is a major risk factor for NASH, and metabolic interventions such as bariatric surgery (BS) and glucagon‐lik...
Saved in:
Main Authors: | Abdallah Hussein, Ameer Awashra, Islam Rajab, Mohammad Bdair, Dawoud Hamdan, Ahmad Nouri, Elaf Khatib, Ghiras Khatib, Nyan Latt |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.70075 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Novel GLP-1 and FGF21 Fusion Protein for the Treatment of Non-alcoholic Steatohepatitis (NASH)
by: Zhipeng Zhang, et al.
Published: (2025-04-01) -
Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01) -
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Chi-Kuei Hsu, et al.
Published: (2025-07-01) -
Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01) -
Integration of Pseudotargeted Metabolomics and Microbiomics Reveals That Hugan Tablets Ameliorate NASH with Liver Fibrosis in Mice by Modulating Bile Acid Metabolism via the Gut Microbiome
by: Wenran Dong, et al.
Published: (2025-06-01)